Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteIdactamab (Anti-SLC1A5 / ASCT2) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used to prepare MEDI7247, a potent and specific ADC targeting ASCT2 (SLC1A5). MW : 145.5 KD.
More Information Supplier PageIdactamab (Anti-SLC1A5 / ASCT2) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used to prepare MEDI7247, a potent and specific ADC targeting ASCT2 (SLC1A5). MW : 145.5 KD.
More Information Supplier PageIdactamab (Anti-SLC1A5 / ASCT2) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used to prepare MEDI7247, a potent and specific ADC targeting ASCT2 (SLC1A5). MW : 145.5 KD.
More Information Supplier PageIdarubicin HCl (4-demethoxydaunorubicin (NSC256439, 4-DMDR) HCl) is a hydrochloride salt form of Idarubicin which is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells with IC50 of 3.3 ng/mL in a cell-free assay. Idarubicin induces mTOR-dependent cytotoxic autophagy.
More Information Supplier PageIdarubicin HCl (4-demethoxydaunorubicin (NSC256439, 4-DMDR) HCl) is a hydrochloride salt form of Idarubicin which is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells with IC50 of 3.3 ng/mL in a cell-free assay. Idarubicin induces mTOR-dependent cytotoxic autophagy.
More Information Supplier PageIdarubicin HCl (4-demethoxydaunorubicin (NSC256439, 4-DMDR) HCl) is a hydrochloride salt form of Idarubicin which is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells with IC50 of 3.3 ng/mL in a cell-free assay. Idarubicin induces mTOR-dependent cytotoxic autophagy.
More Information Supplier PageIdasanutlin (RG7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM showing improved in vitro binding as well as cellular potency/selectivity.
More Information Supplier PageIdasanutlin (RG7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM showing improved in vitro binding as well as cellular potency/selectivity.
More Information Supplier PageIdasanutlin (RG7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM showing improved in vitro binding as well as cellular potency/selectivity.
More Information Supplier PageIdasanutlin (RG7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM showing improved in vitro binding as well as cellular potency/selectivity.
More Information Supplier PageIDE397 (GSK-4362676) is a potent inhibitor of MAT2A(methionine adenosyltransferase 2A) and exhibits anti-tumor activity in MTAP-deleted PDX models.
More Information Supplier PageIDE397 (GSK-4362676) is a potent inhibitor of MAT2A(methionine adenosyltransferase 2A) and exhibits anti-tumor activity in MTAP-deleted PDX models.
More Information Supplier PageIDE397 (GSK-4362676) is a potent inhibitor of MAT2A(methionine adenosyltransferase 2A) and exhibits anti-tumor activity in MTAP-deleted PDX models.
More Information Supplier PageIDE397 (GSK-4362676) is a potent inhibitor of MAT2A(methionine adenosyltransferase 2A) and exhibits anti-tumor activity in MTAP-deleted PDX models.
More Information Supplier PageIDE397 (GSK-4362676) is a potent inhibitor of MAT2A(methionine adenosyltransferase 2A) and exhibits anti-tumor activity in MTAP-deleted PDX models.
More Information Supplier PageIdebenone (CV-2619) is a synthetic analog of coenzyme Q10 (CoQ10) and a brain stimulant.
More Information Supplier PageIdebenone (CV-2619) is a synthetic analog of coenzyme Q10 (CoQ10) and a brain stimulant.
More Information Supplier PageIdelalisib (CAL-101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
More Information Supplier PageIdelalisib (CAL-101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
More Information Supplier PageIdelalisib (CAL-101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
More Information Supplier PageIdelalisib (CAL-101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
More Information Supplier PageIdelalisib (CAL-101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
More Information Supplier PageIDF-11774 is a hypoxia-inducible factor-1 (HIF-1) inhibitor. It reduces the HRE-luciferase activity of HIF-1α (IC50 = 3.65 μM) and blocks HIF-1α accumulation under hypoxia in HCT116 human colon cancer cells.
More Information Supplier PageIDF-11774 is a hypoxia-inducible factor-1 (HIF-1) inhibitor. It reduces the HRE-luciferase activity of HIF-1α (IC50 = 3.65 μM) and blocks HIF-1α accumulation under hypoxia in HCT116 human colon cancer cells.
More Information Supplier PageIDF-11774 is a hypoxia-inducible factor-1 (HIF-1) inhibitor. It reduces the HRE-luciferase activity of HIF-1α (IC50 = 3.65 μM) and blocks HIF-1α accumulation under hypoxia in HCT116 human colon cancer cells.
More Information Supplier PageIDH-305 (Compound 13) is an orally available, mutant-selective and brain-penetrant inhibitor of isocitrate dehydrogenase 1 (IDH1) that targets IDH1(R132) mutation with IC50 of 27 nM, 28 nM and 6.14 μM for IDH1R132H, IDH1R132C and IDH1WT, respectively.
More Information Supplier PageIDH-305 (Compound 13) is an orally available, mutant-selective and brain-penetrant inhibitor of isocitrate dehydrogenase 1 (IDH1) that targets IDH1(R132) mutation with IC50 of 27 nM, 28 nM and 6.14 μM for IDH1R132H, IDH1R132C and IDH1WT, respectively.
More Information Supplier PageIDO inhibitor 1 is a potent inhibitor of IDO (indoleamine-(2,3)-dioxygenase) with IC50 of 3 nM.
More Information Supplier PageIDO inhibitor 1 is a potent inhibitor of IDO (indoleamine-(2,3)-dioxygenase) with IC50 of 3 nM.
More Information Supplier PageIDO-IN-1 is a potent indoleamine 2,3-dioxygenase (IDO) inhibitor with an IC50 of 59 nM.
More Information Supplier PageIDO-IN-2 (RG 6078, NLG-919 analogue, GDC-0919 analogue) is a a potent IDO1 inhibitor with IC50 of 38 nM.
More Information Supplier PageIDO-IN-2 (RG 6078, NLG-919 analogue, GDC-0919 analogue) is a a potent IDO1 inhibitor with IC50 of 38 nM.
More Information Supplier PageIDO-IN-2 (RG 6078, NLG-919 analogue, GDC-0919 analogue) is a a potent IDO1 inhibitor with IC50 of 38 nM.
More Information Supplier PageIDO-IN-2 (RG 6078, NLG-919 analogue, GDC-0919 analogue) is a a potent IDO1 inhibitor with IC50 of 38 nM.
More Information Supplier PageIdoxuridine (NSC 39661, SKF 14287,5-Iodo-2′-deoxyuridine,5-IUdR,IdUrd) is an antiviral agent for feline herpesvirus type-1 with IC50 of 4.3 μM.
More Information Supplier PageIdoxuridine (NSC 39661, SKF 14287,5-Iodo-2′-deoxyuridine,5-IUdR,IdUrd) is an antiviral agent for feline herpesvirus type-1 with IC50 of 4.3 μM.
More Information Supplier PageIDRA-21 is a partial allosteric modulator of AMPA receptor desensitization. IDRA-21 is a potent cognition-enhancing drug virtually devoid of neurotoxic liability.
More Information Supplier PageIdramantone (Kemantane, 5-Hydroxy-2-adamantanone) is an immune agonist.
More Information Supplier PageIEM 1754 2HBr is a selective AMPA/kainate receptor blockers for GluR1 and GluR3 with IC50 of 6 μM.
More Information Supplier PageIeramilimab (Anti-LAG3 / CD223) is a humanized IgG4 monoclonal antibody that targets LAG-3. It has antitumor activity and can be used in treatment of advanced malignancies MW :146.78 KD.
More Information Supplier PageIeramilimab (Anti-LAG3 / CD223) is a humanized IgG4 monoclonal antibody that targets LAG-3. It has antitumor activity and can be used in treatment of advanced malignancies MW :146.78 KD.
More Information Supplier PageIeramilimab (Anti-LAG3 / CD223) is a humanized IgG4 monoclonal antibody that targets LAG-3. It has antitumor activity and can be used in treatment of advanced malignancies MW :146.78 KD.
More Information Supplier PageIfabotuzumab (Anti-EphA3) is a monoclonal antibody against EphA3. MW: 145.28 KD.
More Information Supplier PageIfabotuzumab (Anti-EphA3) is a monoclonal antibody against EphA3. MW: 145.28 KD.
More Information Supplier PageIfabotuzumab (Anti-EphA3) is a monoclonal antibody against EphA3. MW: 145.28 KD.
More Information Supplier PageIfenprodil is an atypical noncompetitive antagonist at the NMDA receptor, it interacts with high affinity at a homogeneous population of NMDA receptors in neonatal rat forebrain with IC50 of 0.3 μM.
More Information Supplier Page
